NCT02620592View on ClinicalTrials.gov

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Diabetes Mellitus

Interventions

DRUG

ZYDPLA1 tablet

The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.

DRUG

Placebo tablet

The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.

Trial Locations (1)

91911

Profil Institute for Clinical Research, Chula Vista

All Listed Sponsors

lead

Zydus Lifesciences Limited

INDUSTRY

NCT02620592 - Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers | Biotech Hunter | Biotech Hunter